Document is current
Any future updates will be listed below
-
Authors
Ao, Jiarui https://orcid.org/0009-0000-2567-2768
Picard, Cynthia https://orcid.org/0000-0003-1107-6839
Auld, Daniel https://orcid.org/0000-0002-9486-1105
Zetterberg, Henrik https://orcid.org/0000-0003-3930-4354
Brinkmalm, Ann
Blennow, Kaj https://orcid.org/0000-0002-1890-4193
Villeneuve, Sylvia
Breitner, John C. S.
Poirier, Judes https://orcid.org/0000-0002-8018-4545
,
Breitner, J.
Poirier, J.
Villeneuve, S.
Zetterberg, H.
Blennow, K.
Baril, A. A.
Geddes, M.
Ducharme, S.
Montembeault, M.
Spreng, N.
Pichet-Bessette, A.
Munter, L.
Tedeshi-Dauar, M.
Picard, C.
Labonté, A.
Aumont-Rodrigue, G.
Ao, J.
Sarty, I.
Loncke, J.
Poirier, A.
-
Funding
Funding for this research was provided by:
Fonds de Recherche du Québec - Santé (FRQ-356162)
Fonds de Recherche du Québec - Santé (FRQ-356162)
Gouvernement du Canada | Natural Sciences and Engineering Research Council of Canada (RGPIN-2020-04702)
Gouvernement du Canada | Canadian Institutes of Health Research (# PJT 153287, 178210)
Gouvernement du Canada | Canadian Institutes of Health Research (PJT: 178385, 438655)
Forskningsrådet om Hälsa, Arbetsliv och Välfärd (#2023-00356; #2022-01018 and #2019-02397)
Forskningsrådet om Hälsa, Arbetsliv och Välfärd (#2017-00915 and #2022-00732)
Alzheimer's Drug Discovery Foundation (#201809-2016862)
Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C, and #ADSF-24-1284328-C)
Alzheimer's Association (SG-23-1038904 QC)
Hjärnfonden (#FO2017-0243 and #ALZ2022-0006)
Fondation Brain Canada
- License Information
-
More Information
Article History
Received: 23 May 2024
Revised: 11 December 2024
Accepted: 27 December 2024
First Online: 18 January 2025
Competing interests
: JP serves as a scientific advisor to the Alzheimer Society of France. HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work).KB has served as a consultant and on advisory boards for Abbvie, AC Immune, ALZPath, AriBio, BioArctic, Biogen, Eisai, Lilly, and Moleac Pte. Ltd, Neurimmune, Novartis, Ono Pharma, Prothena, Roche Diagnostics, and Siemens Healthineers; has served on data monitoring committees for Julius Clinical and Novartis; has given lectures, produced educational materials, and participated in educational programs for AC Immune, Biogen, Celdara Medical, Eisai and Roche Diagnostics; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. All other authors have nothing to disclose.
